Last update 20 Mar 2025

Epidermal growth factor receptor tumour activated T-cell engager therapy (Janux Therapeutics/Merck & Co)

Overview

Basic Info

Drug Type
Bispecific T-cell Engager (BiTE), Probody
Synonyms
EGFR TRACTr Janux Therapeutics/Merck Co, EGFR-TRACTr, EGFRTRACTr
+ [2]
Action
modulators, antagonists
Mechanism
CD3ε modulators(CD3e molecule modulators), EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Colorectal CancerPhase 1
United States
19 Apr 2023
Non-Small Cell Lung CancerPhase 1
United States
19 Apr 2023
Pancreatic Ductal AdenocarcinomaPhase 1
United States
19 Apr 2023
Renal Cell CarcinomaPhase 1
United States
19 Apr 2023
Small Cell Lung CancerPhase 1
United States
19 Apr 2023
Squamous Cell Carcinoma of Head and NeckPhase 1
United States
19 Apr 2023
Triple Negative Breast CancerPhase 1
United States
19 Apr 2023
Solid tumorPreclinical
United States
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Biospace
ManualManual
Phase 1
11
(pwkkknmbya) = qxpdyyintd xhcpjpwnyv (ufcjzzpcuo )
Positive
26 Feb 2024
Not Applicable
586
(EGFR mutation positive)
(jlfrhdjpht) = ftqugkbmzp iohdjcwbhc (jtnuwvsvwl, 25 - 41)
Positive
02 Jun 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free